Treating refractive disorders by targeting peroxisome proliferator-activated receptor (PPAR) signaling pathway

Abstract

A pharmacologic treatment of refractive disorders, specifically myopia or hyperopia, by targeting the PPAR signaling pathway using a PPARγ agonist without any binding to PPARα. It is demonstrated that the PPARγ agonist modulates ocular growth through therapeutic intervention at the protein level of the PPAR signaling pathway. The effectiveness of the PPARγ agonist in regulating the PPAR signaling pathway and its associated proteins, as evidenced by experiments using a lens-induced myopia (LIM) animal model. More particularly, it is also demonstrated that the pharmacological reduction of myopic eye growth in terms of biometrics with dosage effect through the administration of the PPARγ agonist.

Dependencies are inferred from the claim text.